Informed Prostate Cancer Patient Support

Why Age Matters When Treating Prostate Cancer | Cooking with Kathy Man Informed Prostate Cancer Support Group IPCSG Newsletter — San Diego, CA Treatment Decisions May 2026 Treatment Science A landmark meta-analysis, new trial data, and updated guidelines are reshaping how oncologists decide whether — and how aggressively — to treat older men with metastatic disease. The answer, it turns out, depends on far more than the calendar. Informed Prostate Cancer Support Group Newsletter  |  Prepared for IPCSG Members  |  May 2026 For the past decade, the treatment of metastatic hormone-sensitive prostate cancer (mHSPC) has been transformed by a powerful insight: doing more is better. Adding powerful new hormonal agents — and sometimes chemotherapy — to standard hormone therapy dramatically improved survival. The message to oncologists was clear: intensify treatment early. But a growing body of evidence is adding an essential qua...

23andMe offers to connect users’ DNA data with medical records | STAT What Prostate Cancer Patients Really Need to Know IPCSG Informed Prostate Cancer Support Group · San Diego Translating research into answers for patients and families Patient Education Series May 2026 Genomics & Privacy A new announcement promises to combine your DNA data with your health records. Here's why it's far less useful — and far more complicated — than it sounds for men managing prostate cancer. IPCSG Newsletter · Patient Education Article | Reading time: ~12 minutes Bottom Line Up Front (BLUF) On May 20, 2026, 23andMe announced a partnership with HealthEx to let customers link their electronic medical records to their genetic profiles, calling it a "360-degree view" of personal health. For most prostate cancer patients, this o...

  What PCWG4 Means for You Informed Prostate Cancer Support Group (IPCSG) Member Newsletter San Diego, California May 2026 Issue Clinical Trials & Research Update   Prepared for IPCSG Members by the Newsletter Staff • Published May 2026 Bottom Line Up Front (BLUF) An international panel of more than 40 prostate cancer specialists has issued a landmark update — the Prostate Cancer Working Group 4 ( PCWG4 ) report — that rewrites the standards used to design and conduct clinical trials for advanced prostate cancer. Published in February 2026 in the Journal of Clinical Oncology , PCWG4 replaces stigmatizing "castration" language with biology-based terminology, formally integrates the powerful PSMA-PET scan into trial rules, refines how progression is measured so patients are not pulled from beneficial treatments prematurely, and demands that patient quality-of-life ...